Quality of life improvement in HIV-1 patients treated with raltegravir in a real-life observational study: RACING

References

• Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339–354.10.1056/NEJMoa0708975
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2013;63(1):77–85.10.1097/QAI.0b013e31828ace69
   PubMed Web of Science ®Google Scholar
• Boulet T1, Pavie J, Charreau I, et al. Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138) HIV Clin Trials. 2010;11(5):283–29310.1310/hct1105-283
   PubMed Web of Science ®Google Scholar
• Cohen C, Revicki DA, Nabulsi A, Sarocco PW, Jiang P. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. AIDS. 1998 20;12(12):1495–1502.10.1097/00002030-199812000-00012
   PubMed Web of Science ®Google Scholar
• Nglazi MD, West SJ, Dave JA, Levitt NS, Lambert EV. Quality of life in individuals living with HIV/AIDS attending a public sector antiretroviral service in Cape Town, South Africa. BMC Public Health. 2014;14:676. doi: 10.1186/1471-2458-14-676
   PubMed Web of Science ®Google Scholar
• Nieuwkerk PT, Gisolf EH, Colebunders R, Wu AW, Danner SA, Sprangers MA. Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group. AIDS. 2000 Jan 28;14(2):181–187.
   PubMed Web of Science ®Google Scholar
• Jong E, Oudhoff LA, Epskamp C, et al. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era. AIDS. 2010;24(10):1387–1405.10.1097/QAD.0b013e328339d004
   PubMed Web of Science ®Google Scholar
• Adinolfi A. Assessment and treatment of HIV-related fatigue. J Assoc Nurses AIDS Care. 2001;12(Suppl):29–34; quiz 5–8.
   Google Scholar
• Barroso J, Harmon JL, Madison JL, Pence BW. Intensity, chronicity, circumstances, and consequences of HIV-related fatigue: a longitudinal study. Clin Nurs Res. 2014;23(5):514–528.10.1177/1054773813492998
   PubMed Web of Science ®Google Scholar
• Barroso J, Voss JG. Fatigue in HIV and AIDS: an analysis of evidence. J Assoc Nurses AIDS Care. 2013;24(1):S5–S14.10.1016/j.jana.2012.07.003
   PubMed Web of Science ®Google Scholar
• Michel L, Villes V, Dabis F, et al. Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006–2008. J Viral Hepat. 2010;17(9):650–660.
   PubMed Web of Science ®Google Scholar
• Marcellin F, Préau M, Ravaux I, Dellamonica P, Spire B, Carrieri MP. Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. HIV Clin Trials. 2007;8(5):320–32710.1310/hct0805-320
   PubMed Web of Science ®Google Scholar
• Protopopescu C1, Marcellin F, Spire B, et al. Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8) Qual Life Res. 2007;16(4):577–59110.1007/s11136-006-9151-7
   PubMed Web of Science ®Google Scholar
• Spire B, Marcellin F, Cohen-Codar I, et al. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial. Antivir Ther. 2008;13(4):591–599.
   PubMed Web of Science ®Google Scholar
• Pugliese P, Billaud E, Poizot-Martin I, et al. Real life evaluation of HIV-1 infected patients treated with an ARV combination therapy including raltegravir in France the final RACING study results (M24) 14th European AIDS Conference, Brussels, Oct 2013.
   Google Scholar
• Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol. 2001;54(12):S77–S90.10.1016/S0895-4356(01)00449-8
   PubMed Web of Science ®Google Scholar
• Fisk JD, Ritvo PG, Ross L, et al. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994;18(Suppl 1):S79–S83.10.1093/clinids/18.Supplement_1.S79
   PubMed Web of Science ®Google Scholar
• Pence BW, Barroso J, Harmon JL, Leserman J, Salahuddin N, Hammill BG. Chronicity and remission of fatigue in patients with established HIV infection. AIDS Patient Care STDs. 2009;23(4):239–244.10.1089/apc.2008.0175
   PubMed Web of Science ®Google Scholar
• Edelman EJ, Gordon K, Rodriguez-Barradas MC, Justice AC. Patient-Reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir. AIDS Patient Care STDs. 2012;26(6):312–319.10.1089/apc.2012.0044
   PubMed Web of Science ®Google Scholar
• Voss JG. Predictors and correlates of fatigue in HIV/AIDS. J Pain Symptom Manage. 2005;29(2):173–184.10.1016/j.jpainsymman.2004.05.006
   PubMed Web of Science ®Google Scholar
• Préau M, Marcellin F, Carrieri MP, Lert F, Obadia Y, Spire B. Health-related quality of life in French people living with HIV in 2003: results from the national ANRS-EN12-VESPA Study. AIDS. 2007;21(Suppl 1):S19–S27.10.1097/01.aids.0000255081.24105.d7
   PubMed Web of Science ®Google Scholar
• Rourke SB, Bekele T, Tucker R, et al. Housing characteristics and their influence on health-related quality of life in persons living with HIV in Ontario, Canada: results from the positive spaces, healthy places study. AIDS Behav. 2012;16(8):2361–2373.10.1007/s10461-012-0284-0
   PubMed Web of Science ®Google Scholar
• Louwagie GM, Bachmann MO, Meyer K, Booysen Fle R, Fairall LR, Heunis C. Highly active antiretroviral treatment and health related quality of life in South African adults with human immunodeficiency virus infection: a cross-sectional analytical study. BMC Public Health. 2007;7:682.10.1186/1471-2458-7-244
   Web of Science ®Google Scholar
• Bader A, Kremer H, Erlich-Trungenberger I, et al. An adherence typology: coping, quality of life, and physical symptoms of people living with HIV/AIDS and their adherence to antiretroviral treatment. Med Sci Monit. 2006;12(12):CR493–500.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Murri R, Orlando G, et al. Lipodystrophy and quality of life of HIV-infected persons. AIDS Rev. 2008;10(3):152–161.
   PubMed Web of Science ®Google Scholar
• Liu Z, Yang J, Liu H, Jin Y. Factors associated with fatigue in acquired immunodeficiency syndrome patients with antiretroviral drug adverse reactions: a retrospective study. J Tradit Chin Med. 2013;33(3):316–321.10.1016/S0254-6272(13)60172-7
   PubMed Web of Science ®Google Scholar
• Gay C, Portillo CJ, Kelly R, et al. Self-reported medication adherence and symptom experience in adults With HIV. J Assoc Nurses AIDS Care. 2011;22(4):257–268.10.1016/j.jana.2010.11.004
   PubMed Web of Science ®Google Scholar
• Battegay M, Elzi L. Morbidity and mortality in HIV-infected individuals – a shift towards comorbidities. Swiss Med Wkly. 2009;139(39–40):564–570.
   PubMed Web of Science ®Google Scholar
• Protopopescu C, Marcellin F, Spire B, et al. Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8). Qual Life Res. 2007;16(4):577–591.10.1007/s11136-006-9151-7
   PubMed Web of Science ®Google Scholar